Retatrutide Cuts Knee Pain in 2 of 3 Obese OA Patients as Weight Falls 25%

3 articles · Updated · Fox News · Nov 11

Two late-stage trials in more than 1,000 adults found Eli Lilly’s experimental obesity drug retatrutide significantly eased knee osteoarthritis pain and improved mobility after 68 to 80 weeks.
About two-thirds of patients on retatrutide achieved at least a 50% reduction in knee pain, versus 38% on placebo, while those on the highest dose lost roughly a quarter of their body weight.
One in eight treated patients had complete knee-pain relief, and researchers also reported lower blood pressure, improved lipid levels and reduced systemic inflammation.
Gastrointestinal side effects were the most common, and serious adverse events occurred more often with retatrutide than with placebo.
The drug is not yet FDA-approved, and the findings apply only to overweight or obese, non-diabetic patients with moderate knee osteoarthritis—not advanced cases or those needing knee replacement.